Ocular Therapeutix

(NASDAQ) OCUL

Current Price$9.38

Market Cap$2.00B

Since IPO (2014)-30%

5 Year-50%

1 Year+12%

1 Month+24%

Ocular Therapeutix Financials at a Glance

Market Cap

$2.00B

Revenue (TTM)

$51.95M

Net Income (TTM)

$265.94M

EPS (TTM)

$-1.44

P/E Ratio

-6.40

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$9.38

Volume

2,761,248.143

Open

$9.23

Price

$9.38

Volume

2,761,248.143

Open

$9.23

Previous Close

$9.37

Daily Range

$9.12 - $9.39

52-Week Range

$6.23 - $16.44

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$9.38

Volume

2,761,248.143

Open

$9.23

Previous Close

$9.37

Daily Range

$9.12 - $9.39

52-Week Range

$6.23 - $16.44

OCUL News

Page 1

OCUL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ocular Therapeutix

Industry

Pharmaceuticals

Sector

Health Care

Employees

325

CEO

Pravin U. Dugel, MD

Website

www.ocutx.com

Headquarters

Bedford, MA 01730, US

OCUL Financials

Key Financial Metrics (TTM)

Gross Margin

87%

Operating Margin

-5%

Net Income Margin

-5%

Return on Equity

-55%

Return on Capital

-36%

Return on Assets

-33%

Earnings Yield

-15.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.00B

Shares Outstanding

217.69M

Volume

2.76M

Avg. Volume

5.68M

Financials (TTM)

Gross Profit

$45.25M

Operating Income

$270.02M

EBITDA

$249.78M

Operating Cash Flow

$204.88M

Capital Expenditure

$12.01M

Free Cash Flow

$216.89M

Cash & ST Invst.

$737.06M

Total Debt

$79.78M

Ocular Therapeutix Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$13.25M

-22.4%

Gross Profit

$11.66M

-26.5%

Gross Margin

87.97%

N/A

Market Cap

$2.00B

N/A

Market Cap/Employee

$7.32M

N/A

Employees

274

N/A

Net Income

$64.65M

-33.6%

EBITDA

$60.58M

-36.6%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$660.09M

+108.7%

Accounts Receivable

$30.65M

-5.4%

Inventory

$3.56M

+17.2%

Long Term Debt

$74.15M

+0.4%

Short Term Debt

$2.82M

+45.7%

Return on Assets

-32.91%

N/A

Return on Invested Capital

-35.66%

N/A

Free Cash Flow

$57.09M

-44.0%

Operating Cash Flow

$54.25M

-37.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

MESOMesoblast Limited

MESOMesoblast Limited$15.67+0.77%

GLPGGalapagos N.V.

GLPGGalapagos N.V.$27.83-0.11%

GPCRStructure Therapeutics Inc.

GPCRStructure Therapeutics Inc.$41.45+0.21%

RCUSArcus Biosciences, Inc.

RCUSArcus Biosciences, Inc.$25.50+5.68%

QUREuniQure N.V.

QUREuniQure N.V.$19.95+19.25%

VRDNViridian Therapeutics, Inc.

VRDNViridian Therapeutics, Inc.$13.48+1.35%

EWTXEdgewise Therapeutics, Inc.

EWTXEdgewise Therapeutics, Inc.$30.96+1.67%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$12.91+0.04%

SOFISoFi Technologies

SOFISoFi Technologies$16.10+0.04%

AAPLApple

AAPLApple$271.35+0.00%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.63+0.10%

MARAMara Holdings

MARAMara Holdings$11.99+0.12%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.54+0.03%

FFord Motor Company

FFord Motor Company$12.08-0.01%

Questions About OCUL

What is the current price of Ocular Therapeutix?

Ocular Therapeutix is trading at $9.37 per share.

What is the 52-week range for Ocular Therapeutix?

Over the past 52 weeks, Ocular Therapeutix has traded between $6.23 and $16.44.

How much debt does Ocular Therapeutix have?

As of the most recent reporting period, Ocular Therapeutix reported total debt of $76.97M.

How much cash does Ocular Therapeutix have on hand?

Ocular Therapeutix reported $737.06M in cash and cash equivalents in its most recent financial results.

What is Ocular Therapeutix’s dividend yield?

Ocular Therapeutix does not currently have a dividend yield.

Ocular Therapeutix

Ocular Therapeutix Financials at a Glance

OCUL News

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

OCUL Sales Drop 18%

Why Ocular Therapeutix Was Bumping Higher This Week

Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024

Why Shares of Ocular Therapeutix Jumped This Week

Here's Why Ocular Therapeutix Stock Is Sinking Today

This Exciting Biopharma Could Earn You 55% in 12 Months

4 Reasons I Just Bought Ocular Therapeutix Stock

OCUL: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ocular Therapeutix

OCUL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ocular Therapeutix Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OCUL

What is the current price of Ocular Therapeutix?

What is the 52-week range for Ocular Therapeutix?

How much debt does Ocular Therapeutix have?

How much cash does Ocular Therapeutix have on hand?

What is Ocular Therapeutix’s dividend yield?

Premium Investing Services